The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Bechara Mfarrej | EBMT 2018 | Advice for the management of toxicities in CAR-T

Mar 23, 2018

44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, Portugal
Bechara Mfarrej
Institute Paoli-Calmettes, Marseille, FR

  • Bechara Mfarrej discusses cytokine release syndrome (CRS) that is a potentially serious side-effect of CAR-T therapy. 
  • He explains that these side-effects are managed by supportive care but it is important to control the symptoms without eliminating the CAR-T cells.
  • Most toxicities are manageable with dedicated supportive care, he concluded, and cytokine blocking medication can be given in the most extreme cases. 

Advice for the management of toxicities in CAR-T